查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1600551

品牌非专利市场：按产品类型、药物类型、给药途径、适应症、分销管道 - 全球预测 2025-2030

Branded Generics Market by Product (Trade Named Generics, Value-Added), Drug Type (Alkylating Agents, Anti-depressants, Anti-epileptics), Route of Administration, Indication, Distribution Channel - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 195 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

2023年，品牌非专利市场价值为4,323亿美元，预计到2024年将达到4,942.9亿美元，复合年增长率为14.66%，到2030年将达到11,264.3亿美元。

品牌非专利是指製药公司以品牌名称销售的专利到期药物，为学名药​​提供了一种经济高效的替代品，同时保持了品牌忠诚度优势。需要平衡负担能力和品质保证，这使得它在医疗费用昂贵的地区变得至关重要。这些药物通常具有多种治疗应用，用于从慢性疾病到急性护理的广泛治疗，并拥有广泛的最终用户，包括医疗保健提供者、医院和个人消费者。推动品牌非专利成长的关键因素包括慢性病盛行率的增加、对负担得起的药物的需求不断增长以及医疗保健机会有限的新兴市场的重要性日益增加。最新的商机在于利用数位行销管道，透过专注于新兴市场的策略联盟和收购来提高品牌影响力并扩大分销网络。然而，市场面临严格的法规环境、激烈的价格竞争和智慧财产权问题等挑战，这可能会阻碍成长。医疗保健政策的不断演变也存在限制，这可能会影响市场进入和药品价格。创新可以探索生物相似药和个人化医疗的发展，使品牌能够透过专注于患者特定的解决方案来脱颖而出。此外，品牌可以透过投资先进的药物输送机制和数位健康监测工具来获得竞争优势。品牌非专利市场竞争温和，众多全球和地区公司争夺市场占有率，需要持续创新和以客户为导向的策略。为了实现永续成长，我们建议投资研发、优化供应链效率、优先考虑新兴打入市场策略并积极应对监管变化。营运敏捷性和强大的品牌差异化对于克服限制和抓住市场机会至关重要。

主要市场统计
基准年[2023] 4323亿美元
预测年份 [2024] 4942.9亿美元
预测年份 [2030] 1,126,430 百万美元
复合年增长率（%） 14.66%

市场动态：揭示快速发展的品牌非专利市场的关键市场洞察

供需的动态交互作用正在改变品牌非专利市场。透过了解这些不断变化的市场动态，公司可以准备好做出明智的投资决策、完善策略决策并抓住新的商机。全面了解这些趋势可以帮助企业降低政治、地理、技术、社会和经济领域的风险，同时消费行为及其对製造成本的影响以及对采购趋势的影响。

  • 市场驱动因素
    • 需要使用学名药的慢性疾病流行
    • 重磅药物专利到期增加以及对具有成本效益的替代品的需求增加
  • 市场限制因素
    • 对品牌学名药品质差异的担忧
  • 市场机会
    • 新的生物等效性测试和市场参与企业为扩大品牌非专利业务所做的努力
  • 市场挑战
    • 诉讼问题及新药价格下跌相关问题

波特的五力：驾驭品牌非专利市场的策略工具

波特的五力框架是理解市场竞争格局的重要工具。波特的五力框架为评估公司的竞争地位和探索策略机会提供了清晰的方法。该框架可帮助公司评估市场动态并确定新业务的盈利。这些见解使公司能够利用自己的优势，解决弱点并避免潜在的挑战，从而确保更强大的市场地位。

PESTLE分析：了解品牌非专利市场的外部影响

外部宏观环境因素在塑造品牌非专利市场的绩效动态方面发挥着至关重要的作用。对政治、经济、社会、技术、法律和环境因素的分析提供了应对这些影响所需的资讯。透过调查 PESTLE 因素，公司可以更了解潜在的风险和机会。这种分析可以帮助公司预测法规、消费者偏好和经济趋势的变化，并为他们做出积极主动的决策做好准备。

市场占有率分析 了解品牌非专利市场的竞争状况

对品牌非专利市场的详细市场占有率分析可以对供应商绩效进行全面评估。公司可以透过比较收益、客户群和成长率等关键指标来揭示其竞争地位。该分析揭示了市场集中、分散和整合的趋势，为供应商提供了製定策略决策所需的洞察力，使他们能够在日益激烈的竞争中占有一席之地。

FPNV 品牌非专利市场定位矩阵供应商绩效评估

FPNV定位矩阵是评估品牌非专利市场供应商的重要工具。此矩阵允许业务组织根据供应商的商务策略和产品满意度评估供应商，从而做出符合其目标的明智决策。四个象限清楚且准确地划分供应商，帮助使用者辨识最能满足其策略目标的合作伙伴和解决方案。

本报告提供了涵盖关键重点领域的全面市场分析：

1. 市场渗透率：对当前市场环境的详细回顾，包括行业主要企业的大量资料。

2. 市场开拓：辨识新兴市场的成长机会，评估现有领域的扩张潜力，并提供未来成长的策略蓝图。

3. 市场多元化：分析近期产品发布、开拓地区、关键产业进展、塑造市场的策略投资。

4. 竞争评估与情报：彻底分析竞争格局，检验市场占有率、业务策略、产品系列、认证、监理核准、专利趋势、主要企业的技术进步等。

5. 产品开发与创新：重点在于有望推动未来市场成长的最尖端科技、研发活动和产品创新。

我们也回答重要问题，以帮助相关人员做出明智的决策：

1.目前的市场规模和未来的成长预测是多少？

2. 哪些产品、区隔市场和地区提供最佳投资机会？

3.塑造市场的主要技术趋势和监管影响是什么？

4.主要厂商的市场占有率和竞争地位如何？

5. 推动供应商市场进入和退出策略的收益来源和策略机会是什么？

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • 需要使用学名药的慢性病的流行
      • 重磅药物专利到期的增加和对具有成本效益的替代品的需求增加
    • 抑制因素
      • 对品牌学名药品质差异的担忧
    • 机会
      • 新的生物等效性研究和市场参与者扩大品牌非专利业务的努力
    • 任务
      • 与诉讼问题和品牌药价格下跌相关的问题
  • 市场区隔分析
    • 产品：大量采用付加品牌非专利可带来额外好处
    • 药物类型：抗高血压药物通常用于治疗高血压。
    • 给药途径：口服给药因其作用时间长而被广泛采用。
    • 适应症：品牌非专利在胃肠道和神经系统疾病的使用激增
    • 分销管道：品牌非专利线上分销管道的演变
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 经济
    • 社群
    • 技术的
    • 合法地
    • 环境

第六章 品牌非专利市场：副产品

  • 产品名称学名药
  • 付加

第七章 品牌非专利市场药品（按类型）

  • 烷化剂
  • 抗忧郁症
  • 抗癫痫药
  • 抗高血压药
  • 抗精神病药物
  • 抗代谢物
  • 荷尔蒙
  • 降血脂药

第八章 品牌非专利市场：依管理途径

  • 口服
  • 胃肠外的
  • 话题

第九章以适应症分類的品牌非专利市场

  • 急性和慢性疼痛
  • 心血管疾病
  • 皮肤病
  • 消化系统疾病
  • 神经系统疾病
  • 肿瘤学

第 10 章 品牌非专利市场：按分销管道

  • 离线
    • 医院药房
    • 零售药房
  • 在线的

第十一章 美洲品牌非专利市场

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第十二章亚太品牌非专利市场

  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第十三章欧洲、中东和非洲的品牌非专利市场

  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第14章竞争格局

  • 2023 年市场占有率分析
  • FPNV 定位矩阵，2023
  • 竞争情境分析
    • Vyvanse非专利获 FDA核准
    • 药联会与学名药协会更新学名药定价协议
    • Amneal 推出经批准的 Xyrem（奥昔巴特钠）非专利，并获得 FDA核准5 种复合非专利
    • Ajanta Pharma 旨在扩大快速成长的亚洲和非洲地区的业务
    • 雷迪博士进军国内市场学名药业务
    • Sun Pharma 推出辉瑞重磅抗癌药物的非专利药
    • Zentiva 完成对西班牙 Tiromed 的主要产品收购
    • Cipla推出“Easy Lux L”，一种缓解便秘的无糖口服乳液泻药
    • ProCaps Group 从 Advent International 收购 Grupo Somar

公司名单

  • Dr. Reddy's Laboratories Ltd.
  • Lupin Limited
  • Viatris Inc.
  • Sandoz International GmbH by Novartis AG
  • Bausch Health Companies Inc.
  • GlaxoSmithKline PLC
  • Amneal Pharmaceuticals LLC
  • Eris Lifesciences Limited
  • Alkem Laboratories Ltd.
  • Cipla Limited
  • Zentiva Group, as
  • Nichi-Iko Pharmaceutical Co., Ltd.
  • Endo International PLC
  • Aurobindo Pharma Limited
  • AstraZeneca PLC
  • Eva Pharma
  • Hetero Drugs Limited
  • Abbott Laboratories
  • Glenmark Pharmaceuticals Limited
  • Fresenius Kabi AG
  • Pfizer Inc.
  • Aspen Pharmacare Holdings Limited
  • Sun Pharmaceutical Industries Ltd.
  • Ajanta Pharma Ltd.
  • Apotex Inc.
  • Bristol-Myers Squibb Company
  • Sanofi SA
  • Micro Labs Limited
  • Torrent Pharmaceuticals Ltd.
  • Teva Pharmaceutical Industries Ltd.
Product Code: MRR-A26E0E57422E

The Branded Generics Market was valued at USD 432.30 billion in 2023, expected to reach USD 494.29 billion in 2024, and is projected to grow at a CAGR of 14.66%, to USD 1,126.43 billion by 2030.

Branded generics refer to off-patent drugs that are sold under a brand name by pharmaceutical companies, offering a cost-effective alternative to generic drugs while retaining brand loyalty advantages. Their necessity arises from the balance they offer between affordability and quality assurance, making them integral in regions where healthcare costs are critical. These drugs are typically applied across multiple therapeutic areas, used in treatments from chronic diseases to acute care, with end-users ranging from healthcare providers, hospitals, and individual consumers. Key factors driving the growth of branded generics include an increase in the prevalence of chronic diseases, rising demand for affordable medication, and expansion in emerging markets where healthcare access is limited yet increasingly crucial. Latest opportunities lie in leveraging digital marketing channels to enhance brand presence and focusing on strategic partnerships or acquisitions in emerging markets to widen distribution networks. However, the market faces challenges such as stringent regulatory environments, fierce price competition, and intellectual property concerns, which can hinder growth. Limitations also stem from the constant evolution of healthcare policies that can affect market access and drug pricing. Innovations could explore the development of biosimilars and personalized medicine as brands could differentiate by focusing on patient-specific solutions. Additionally, investing in advanced drug delivery mechanisms and digital health monitoring tools could provide brands a competitive edge. The nature of the branded generics market is moderately competitive, with numerous global and regional players striving for market share, necessitating continual innovation and customer-oriented strategies. For sustained growth, companies are recommended to invest in R&D, optimize supply chain efficiency, and prioritize emerging market entry strategies while adapting to regulatory changes proactively. The need for both operational agility and strong brand differentiation is paramount in capturing market opportunities while navigating the limitations.

KEY MARKET STATISTICS
Base Year [2023] USD 432.30 billion
Estimated Year [2024] USD 494.29 billion
Forecast Year [2030] USD 1,126.43 billion
CAGR (%) 14.66%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Branded Generics Market

The Branded Generics Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Prevalence of chronic diseases necessitating the use of generic medications
    • Increasing patent expiration for blockbuster drugs and the need for cost-effective alternatives
  • Market Restraints
    • Concerns associated with quality variations in branded generic medications
  • Market Opportunities
    • Novel bioequivalence studies and efforts by market players to expand branded generics business
  • Market Challenges
    • Litigation issues and issues related to price erosion of innovator drugs

Porter's Five Forces: A Strategic Tool for Navigating the Branded Generics Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Branded Generics Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Branded Generics Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Branded Generics Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Branded Generics Market

A detailed market share analysis in the Branded Generics Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Branded Generics Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Branded Generics Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Key Company Profiles

The report delves into recent significant developments in the Branded Generics Market, highlighting leading vendors and their innovative profiles. These include Dr. Reddy's Laboratories Ltd., Lupin Limited, Viatris Inc., Sandoz International GmbH by Novartis AG, Bausch Health Companies Inc., GlaxoSmithKline PLC, Amneal Pharmaceuticals LLC, Eris Lifesciences Limited, Alkem Laboratories Ltd., Cipla Limited, Zentiva Group, a.s., Nichi-Iko Pharmaceutical Co., Ltd., Endo International PLC, Aurobindo Pharma Limited, AstraZeneca PLC, Eva Pharma, Hetero Drugs Limited, Abbott Laboratories, Glenmark Pharmaceuticals Limited, Fresenius Kabi AG, Pfizer Inc., Aspen Pharmacare Holdings Limited, Sun Pharmaceutical Industries Ltd., Ajanta Pharma Ltd., Apotex Inc., Bristol-Myers Squibb Company, Sanofi S.A., Micro Labs Limited, Torrent Pharmaceuticals Ltd., and Teva Pharmaceutical Industries Ltd..

Market Segmentation & Coverage

This research report categorizes the Branded Generics Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Product, market is studied across Trade Named Generics and Value-Added.
  • Based on Drug Type, market is studied across Alkylating Agents, Anti-depressants, Anti-epileptics, Anti-hypertensive, Anti-psychotics, Antimetabolites, Hormones, and Lipid Lowering Drugs.
  • Based on Route of Administration, market is studied across Oral, Parenteral, and Topical.
  • Based on Indication, market is studied across Acute & Chronic Pain, Cardiovascular Diseases, Dermatological Diseases, Gastrointestinal Diseases, Neurological Diseases, and Oncology.
  • Based on Distribution Channel, market is studied across Offline and Online. The Offline is further studied across Hospital Pharmacy and Retail Pharmacy.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Prevalence of chronic diseases necessitating the use of generic medications
      • 5.1.1.2. Increasing patent expiration for blockbuster drugs and the need for cost-effective alternatives
    • 5.1.2. Restraints
      • 5.1.2.1. Concerns associated with quality variations in branded generic medications
    • 5.1.3. Opportunities
      • 5.1.3.1. Novel bioequivalence studies and efforts by market players to expand branded generics business
    • 5.1.4. Challenges
      • 5.1.4.1. Litigation issues and issues related to price erosion of innovator drugs
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Product: Significant adoption of value-added branded generics due to their additional advantages
    • 5.2.2. Drug Type: High usage of anti-hypertensive for treating high blood pressure
    • 5.2.3. Route of Administration: Wide adoption of oral route due to their longer duration of action
    • 5.2.4. Indication: Burgeoning utilization of branded generics for gastrointestinal diseases and neurological diseases
    • 5.2.5. Distribution Channel: Evolving online distribution channels for branded generics
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Branded Generics Market, by Product

  • 6.1. Introduction
  • 6.2. Trade Named Generics
  • 6.3. Value-Added

7. Branded Generics Market, by Drug Type

  • 7.1. Introduction
  • 7.2. Alkylating Agents
  • 7.3. Anti-depressants
  • 7.4. Anti-epileptics
  • 7.5. Anti-hypertensive
  • 7.6. Anti-psychotics
  • 7.7. Antimetabolites
  • 7.8. Hormones
  • 7.9. Lipid Lowering Drugs

8. Branded Generics Market, by Route of Administration

  • 8.1. Introduction
  • 8.2. Oral
  • 8.3. Parenteral
  • 8.4. Topical

9. Branded Generics Market, by Indication

  • 9.1. Introduction
  • 9.2. Acute & Chronic Pain
  • 9.3. Cardiovascular Diseases
  • 9.4. Dermatological Diseases
  • 9.5. Gastrointestinal Diseases
  • 9.6. Neurological Diseases
  • 9.7. Oncology

10. Branded Generics Market, by Distribution Channel

  • 10.1. Introduction
  • 10.2. Offline
    • 10.2.1. Hospital Pharmacy
    • 10.2.2. Retail Pharmacy
  • 10.3. Online

11. Americas Branded Generics Market

  • 11.1. Introduction
  • 11.2. Argentina
  • 11.3. Brazil
  • 11.4. Canada
  • 11.5. Mexico
  • 11.6. United States

12. Asia-Pacific Branded Generics Market

  • 12.1. Introduction
  • 12.2. Australia
  • 12.3. China
  • 12.4. India
  • 12.5. Indonesia
  • 12.6. Japan
  • 12.7. Malaysia
  • 12.8. Philippines
  • 12.9. Singapore
  • 12.10. South Korea
  • 12.11. Taiwan
  • 12.12. Thailand
  • 12.13. Vietnam

13. Europe, Middle East & Africa Branded Generics Market

  • 13.1. Introduction
  • 13.2. Denmark
  • 13.3. Egypt
  • 13.4. Finland
  • 13.5. France
  • 13.6. Germany
  • 13.7. Israel
  • 13.8. Italy
  • 13.9. Netherlands
  • 13.10. Nigeria
  • 13.11. Norway
  • 13.12. Poland
  • 13.13. Qatar
  • 13.14. Russia
  • 13.15. Saudi Arabia
  • 13.16. South Africa
  • 13.17. Spain
  • 13.18. Sweden
  • 13.19. Switzerland
  • 13.20. Turkey
  • 13.21. United Arab Emirates
  • 13.22. United Kingdom

14. Competitive Landscape

  • 14.1. Market Share Analysis, 2023
  • 14.2. FPNV Positioning Matrix, 2023
  • 14.3. Competitive Scenario Analysis
    • 14.3.1. Vyvanse Generics Approved by FDA
    • 14.3.2. Pharmaceutical Alliance, Generic Pharmaceutical Association Renew Generic Drug Pricing Agreement
    • 14.3.3. Amneal Launches Authorized Generic for Xyrem (sodium oxybate) and Receives FDA Approval for Five Complex Generics
    • 14.3.4. Ajanta Pharma looks to expand ops in high-growth Asian, African geographies
    • 14.3.5. Dr Reddy's Enters Trade Generics Business In Domestic Market
    • 14.3.6. Sun Pharma Launches Generic Version of Pfizer's Blockbuster Cancer Drug
    • 14.3.7. Zentiva Completes Major Product Acquisition From Tillomed Spain
    • 14.3.8. Cipla Launches 'Easylax L',A Sugar-Free Oral Emulsion Laxative For Constipation Relief
    • 14.3.9. Procaps Group to Acquire Grupo Somar from Advent International

Companies Mentioned

  • 1. Dr. Reddy's Laboratories Ltd.
  • 2. Lupin Limited
  • 3. Viatris Inc.
  • 4. Sandoz International GmbH by Novartis AG
  • 5. Bausch Health Companies Inc.
  • 6. GlaxoSmithKline PLC
  • 7. Amneal Pharmaceuticals LLC
  • 8. Eris Lifesciences Limited
  • 9. Alkem Laboratories Ltd.
  • 10. Cipla Limited
  • 11. Zentiva Group, a.s.
  • 12. Nichi-Iko Pharmaceutical Co., Ltd.
  • 13. Endo International PLC
  • 14. Aurobindo Pharma Limited
  • 15. AstraZeneca PLC
  • 16. Eva Pharma
  • 17. Hetero Drugs Limited
  • 18. Abbott Laboratories
  • 19. Glenmark Pharmaceuticals Limited
  • 20. Fresenius Kabi AG
  • 21. Pfizer Inc.
  • 22. Aspen Pharmacare Holdings Limited
  • 23. Sun Pharmaceutical Industries Ltd.
  • 24. Ajanta Pharma Ltd.
  • 25. Apotex Inc.
  • 26. Bristol-Myers Squibb Company
  • 27. Sanofi S.A.
  • 28. Micro Labs Limited
  • 29. Torrent Pharmaceuticals Ltd.
  • 30. Teva Pharmaceutical Industries Ltd.

LIST OF FIGURES

  • FIGURE 1. BRANDED GENERICS MARKET RESEARCH PROCESS
  • FIGURE 2. BRANDED GENERICS MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL BRANDED GENERICS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL BRANDED GENERICS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL BRANDED GENERICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL BRANDED GENERICS MARKET SIZE, BY PRODUCT, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL BRANDED GENERICS MARKET SIZE, BY PRODUCT, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL BRANDED GENERICS MARKET SIZE, BY DRUG TYPE, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL BRANDED GENERICS MARKET SIZE, BY DRUG TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL BRANDED GENERICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL BRANDED GENERICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL BRANDED GENERICS MARKET SIZE, BY INDICATION, 2023 VS 2030 (%)
  • FIGURE 13. GLOBAL BRANDED GENERICS MARKET SIZE, BY INDICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. GLOBAL BRANDED GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2030 (%)
  • FIGURE 15. GLOBAL BRANDED GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. AMERICAS BRANDED GENERICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. AMERICAS BRANDED GENERICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. UNITED STATES BRANDED GENERICS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 19. UNITED STATES BRANDED GENERICS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. ASIA-PACIFIC BRANDED GENERICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 21. ASIA-PACIFIC BRANDED GENERICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 22. EUROPE, MIDDLE EAST & AFRICA BRANDED GENERICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 23. EUROPE, MIDDLE EAST & AFRICA BRANDED GENERICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 24. BRANDED GENERICS MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 25. BRANDED GENERICS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. BRANDED GENERICS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL BRANDED GENERICS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL BRANDED GENERICS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL BRANDED GENERICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. BRANDED GENERICS MARKET DYNAMICS
  • TABLE 7. GLOBAL BRANDED GENERICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL BRANDED GENERICS MARKET SIZE, BY TRADE NAMED GENERICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL BRANDED GENERICS MARKET SIZE, BY VALUE-ADDED, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL BRANDED GENERICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL BRANDED GENERICS MARKET SIZE, BY ALKYLATING AGENTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL BRANDED GENERICS MARKET SIZE, BY ANTI-DEPRESSANTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL BRANDED GENERICS MARKET SIZE, BY ANTI-EPILEPTICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL BRANDED GENERICS MARKET SIZE, BY ANTI-HYPERTENSIVE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL BRANDED GENERICS MARKET SIZE, BY ANTI-PSYCHOTICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL BRANDED GENERICS MARKET SIZE, BY ANTIMETABOLITES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL BRANDED GENERICS MARKET SIZE, BY HORMONES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL BRANDED GENERICS MARKET SIZE, BY LIPID LOWERING DRUGS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL BRANDED GENERICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL BRANDED GENERICS MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL BRANDED GENERICS MARKET SIZE, BY PARENTERAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL BRANDED GENERICS MARKET SIZE, BY TOPICAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL BRANDED GENERICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL BRANDED GENERICS MARKET SIZE, BY ACUTE & CHRONIC PAIN, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 25. GLOBAL BRANDED GENERICS MARKET SIZE, BY CARDIOVASCULAR DISEASES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 26. GLOBAL BRANDED GENERICS MARKET SIZE, BY DERMATOLOGICAL DISEASES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 27. GLOBAL BRANDED GENERICS MARKET SIZE, BY GASTROINTESTINAL DISEASES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 28. GLOBAL BRANDED GENERICS MARKET SIZE, BY NEUROLOGICAL DISEASES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 29. GLOBAL BRANDED GENERICS MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 30. GLOBAL BRANDED GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 31. GLOBAL BRANDED GENERICS MARKET SIZE, BY OFFLINE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 32. GLOBAL BRANDED GENERICS MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 33. GLOBAL BRANDED GENERICS MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 34. GLOBAL BRANDED GENERICS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 35. GLOBAL BRANDED GENERICS MARKET SIZE, BY ONLINE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 36. AMERICAS BRANDED GENERICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 37. AMERICAS BRANDED GENERICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 38. AMERICAS BRANDED GENERICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 39. AMERICAS BRANDED GENERICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 40. AMERICAS BRANDED GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 41. AMERICAS BRANDED GENERICS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 42. AMERICAS BRANDED GENERICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 43. ARGENTINA BRANDED GENERICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 44. ARGENTINA BRANDED GENERICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 45. ARGENTINA BRANDED GENERICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 46. ARGENTINA BRANDED GENERICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 47. ARGENTINA BRANDED GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 48. ARGENTINA BRANDED GENERICS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 49. BRAZIL BRANDED GENERICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 50. BRAZIL BRANDED GENERICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 51. BRAZIL BRANDED GENERICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 52. BRAZIL BRANDED GENERICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 53. BRAZIL BRANDED GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 54. BRAZIL BRANDED GENERICS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 55. CANADA BRANDED GENERICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 56. CANADA BRANDED GENERICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 57. CANADA BRANDED GENERICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 58. CANADA BRANDED GENERICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 59. CANADA BRANDED GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 60. CANADA BRANDED GENERICS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 61. MEXICO BRANDED GENERICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 62. MEXICO BRANDED GENERICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 63. MEXICO BRANDED GENERICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 64. MEXICO BRANDED GENERICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 65. MEXICO BRANDED GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 66. MEXICO BRANDED GENERICS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 67. UNITED STATES BRANDED GENERICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 68. UNITED STATES BRANDED GENERICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 69. UNITED STATES BRANDED GENERICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 70. UNITED STATES BRANDED GENERICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 71. UNITED STATES BRANDED GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 72. UNITED STATES BRANDED GENERICS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 73. UNITED STATES BRANDED GENERICS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 74. ASIA-PACIFIC BRANDED GENERICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 75. ASIA-PACIFIC BRANDED GENERICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 76. ASIA-PACIFIC BRANDED GENERICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 77. ASIA-PACIFIC BRANDED GENERICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 78. ASIA-PACIFIC BRANDED GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 79. ASIA-PACIFIC BRANDED GENERICS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 80. ASIA-PACIFIC BRANDED GENERICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 81. AUSTRALIA BRANDED GENERICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 82. AUSTRALIA BRANDED GENERICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 83. AUSTRALIA BRANDED GENERICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 84. AUSTRALIA BRANDED GENERICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 85. AUSTRALIA BRANDED GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 86. AUSTRALIA BRANDED GENERICS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 87. CHINA BRANDED GENERICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 88. CHINA BRANDED GENERICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 89. CHINA BRANDED GENERICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 90. CHINA BRANDED GENERICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 91. CHINA BRANDED GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 92. CHINA BRANDED GENERICS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 93. INDIA BRANDED GENERICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 94. INDIA BRANDED GENERICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 95. INDIA BRANDED GENERICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 96. INDIA BRANDED GENERICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 97. INDIA BRANDED GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 98. INDIA BRANDED GENERICS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 99. INDONESIA BRANDED GENERICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 100. INDONESIA BRANDED GENERICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 101. INDONESIA BRANDED GENERICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 102. INDONESIA BRANDED GENERICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 103. INDONESIA BRANDED GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 104. INDONESIA BRANDED GENERICS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 105. JAPAN BRANDED GENERICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 106. JAPAN BRANDED GENERICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 107. JAPAN BRANDED GENERICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 108. JAPAN BRANDED GENERICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 109. JAPAN BRANDED GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 110. JAPAN BRANDED GENERICS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 111. MALAYSIA BRANDED GENERICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 112. MALAYSIA BRANDED GENERICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 113. MALAYSIA BRANDED GENERICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 114. MALAYSIA BRANDED GENERICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 115. MALAYSIA BRANDED GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 116. MALAYSIA BRANDED GENERICS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 117. PHILIPPINES BRANDED GENERICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 118. PHILIPPINES BRANDED GENERICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 119. PHILIPPINES BRANDED GENERICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 120. PHILIPPINES BRANDED GENERICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 121. PHILIPPINES BRANDED GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 122. PHILIPPINES BRANDED GENERICS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 123. SINGAPORE BRANDED GENERICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 124. SINGAPORE BRANDED GENERICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 125. SINGAPORE BRANDED GENERICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 126. SINGAPORE BRANDED GENERICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 127. SINGAPORE BRANDED GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 128. SINGAPORE BRANDED GENERICS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 129. SOUTH KOREA BRANDED GENERICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 130. SOUTH KOREA BRANDED GENERICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 131. SOUTH KOREA BRANDED GENERICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 132. SOUTH KOREA BRANDED GENERICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 133. SOUTH KOREA BRANDED GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 134. SOUTH KOREA BRANDED GENERICS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 135. TAIWAN BRANDED GENERICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 136. TAIWAN BRANDED GENERICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 137. TAIWAN BRANDED GENERICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 138. TAIWAN BRANDED GENERICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 139. TAIWAN BRANDED GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 140. TAIWAN BRANDED GENERICS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 141. THAILAND BRANDED GENERICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 142. THAILAND BRANDED GENERICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 143. THAILAND BRANDED GENERICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 144. THAILAND BRANDED GENERICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 145. THAILAND BRANDED GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 146. THAILAND BRANDED GENERICS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 147. VIETNAM BRANDED GENERICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 148. VIETNAM BRANDED GENERICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 149. VIETNAM BRANDED GENERICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 150. VIETNAM BRANDED GENERICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 151. VIETNAM BRANDED GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 152. VIETNAM BRANDED GENERICS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 153. EUROPE, MIDDLE EAST & AFRICA BRANDED GENERICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 154. EUROPE, MIDDLE EAST & AFRICA BRANDED GENERICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 155. EUROPE, MIDDLE EAST & AFRICA BRANDED GENERICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 156. EUROPE, MIDDLE EAST & AFRICA BRANDED GENERICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 157. EUROPE, MIDDLE EAST & AFRICA BRANDED GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 158. EUROPE, MIDDLE EAST & AFRICA BRANDED GENERICS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 159. EUROPE, MIDDLE EAST & AFRICA BRANDED GENERICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 160. DENMARK BRANDED GENERICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 161. DENMARK BRANDED GENERICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 162. DENMARK BRANDED GENERICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 163. DENMARK BRANDED GENERICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 164. DENMARK BRANDED GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 165. DENMARK BRANDED GENERICS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 166. EGYPT BRANDED GENERICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 167. EGYPT BRANDED GENERICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 168. EGYPT BRANDED GENERICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 169. EGYPT BRANDED GENERICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 170. EGYPT BRANDED GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 171. EGYPT BRANDED GENERICS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 172. FINLAND BRANDED GENERICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 173. FINLAND BRANDED GENERICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 174. FINLAND BRANDED GENERICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 175. FINLAND BRANDED GENERICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 176. FINLAND BRANDED GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 177. FINLAND BRANDED GENERICS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 178. FRANCE BRANDED GENERICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 179. FRANCE BRANDED GENERICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 180. FRANCE BRANDED GENERICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 181. FRANCE BRANDED GENERICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 182. FRANCE BRANDED GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 183. FRANCE BRANDED GENERICS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 184. GERMANY BRANDED GENERICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 185. GERMANY BRANDED GENERICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 186. GERMANY BRANDED GENERICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 187. GERMANY BRANDED GENERICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 188. GERMANY BRANDED GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 189. GERMANY BRANDED GENERICS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 190. ISRAEL BRANDED GENERICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 191. ISRAEL BRANDED GENERICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 192. ISRAEL BRANDED GENERICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 193. ISRAEL BRANDED GENERICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 194. ISRAEL BRANDED GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 195. ISRAEL BRANDED GENERICS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 196. ITALY BRANDED GENERICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 197. ITALY BRANDED GENERICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 198. ITALY BRANDED GENERICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 199. ITALY BRANDED GENERICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 200. ITALY BRANDED GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 201. ITALY BRANDED GENERICS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 202. NETHERLANDS BRANDED GENERICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 203. NETHERLANDS BRANDED GENERICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 204. NETHERLANDS BRANDED GENERICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 205. NETHERLANDS BRANDED GENERICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 206. NETHERLANDS BRANDED GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 207. NETHERLANDS BRANDED GENERICS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 208. NIGERIA BRANDED GENERICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 209. NIGERIA BRANDED GENERICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 210. NIGERIA BRANDED GENERICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 211. NIGERIA BRANDED GENERICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 212. NIGERIA BRANDED GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 213. NIGERIA BRANDED GENERICS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 214. NORWAY BRANDED GENERICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 215. NORWAY BRANDED GENERICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 216. NORWAY BRANDED GENERICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 217. NORWAY BRANDED GENERICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 218. NORWAY BRANDED GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 219. NORWAY BRANDED GENERICS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 220. POLAND BRANDED GENERICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 221. POLAND BRANDED GENERICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 222. POLAND BRANDED GENERICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 223. POLAND BRANDED GENERICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 224. POLAND BRANDED GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 225. POLAND BRANDED GENERICS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 226. QATAR BRANDED GENERICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 227. QATAR BRANDED GENERICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 228. QATAR BRANDED GENERICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 229. QATAR BRANDED GENERICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 230. QATAR BRANDED GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 231. QATAR BRANDED GENERICS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 232. RUSSIA BRANDED GENERICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 233. RUSSIA BRANDED GENERICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 234. RUSSIA BRANDED GENERICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 235. RUSSIA BRANDED GENERICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 236. RUSSIA BRANDED GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 237. RUSSIA BRANDED GENERICS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 238. SAUDI ARABIA BRANDED GENERICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 239. SAUDI ARABIA BRANDED GENERICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 240. SAUDI ARABIA BRANDED GENERICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 241. SAUDI ARABIA BRANDED GENERICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 242. SAUDI ARABIA BRANDED GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 243. SAUDI ARABIA BRANDED GENERICS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 244. SOUTH AFRICA BRANDED GENERICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 245. SOUTH AFRICA BRANDED GENERICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 246. SOUTH AFRICA BRANDED GENERICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 247. SOUTH AFRICA BRANDED GENERICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 248. SOUTH AFRICA BRANDED GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 249. SOUTH AFRICA BRANDED GENERICS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 250. SPAIN BRANDED GENERICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 251. SPAIN BRANDED GENERICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 252. SPAIN BRANDED GENERICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 253. SPAIN BRANDED GENERICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 254. SPAIN BRANDED GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 255. SPAIN BRANDED GENERICS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 256. SWEDEN BRANDED GENERICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 257. SWEDEN BRANDED GENERICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 258. SWEDEN BRANDED GENERICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 259. SWEDEN BRANDED GENERICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 260. SWEDEN BRANDED GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 261. SWEDEN BRANDED GENERICS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 262. SWITZERLAND BRANDED GENERICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 263. SWITZERLAND BRANDED GENERICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 264. SWITZERLAND BRANDED GENERICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 265. SWITZERLAND BRANDED GENERICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 266. SWITZERLAND BRANDED GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 267. SWITZERLAND BRANDED GENERICS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 268. TURKEY BRANDED GENERICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 269. TURKEY BRANDED GENERICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 270. TURKEY BRANDED GENERICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 271. TURKEY BRANDED GENERICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 272. TURKEY BRANDED GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 273. TURKEY BRANDED GENERICS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 274. UNITED ARAB EMIRATES BRANDED GENERICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 275. UNITED ARAB EMIRATES BRANDED GENERICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 276. UNITED ARAB EMIRATES BRANDED GENERICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 277. UNITED ARAB EMIRATES BRANDED GENERICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 278. UNITED ARAB EMIRATES BRANDED GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 279. UNITED ARAB EMIRATES BRANDED GENERICS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 280. UNITED KINGDOM BRANDED GENERICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 281. UNITED KINGDOM BRANDED GENERICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 282. UNITED KINGDOM BRANDED GENERICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 283. UNITED KINGDOM BRANDED GENERICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 284. UNITED KINGDOM BRANDED GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 285. UNITED KINGDOM BRANDED GENERICS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 286. BRANDED GENERICS MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 287. BRANDED GENERICS MARKET, FPNV POSITIONING MATRIX, 2023